UPC Analytics
DEEN
Übersicht · Eingereicht: —

ACT_589997/2023

System for ambulatory drug infusion comprising a filling apparatus for flexible containers

NichtigkeitHauptnichtigkeitsklageParis CDRevocation Action—
ÜbersichtEntscheidungenBegründungDokumenteZeitverlauf
Parteien

Kläger

  • Tandem Diabetes Care, Inc.
  • Tandem Diabetes Care Europe B.V.
Vertreter: Charlotte Garnitsch (Taylor Wessing N.V.); Wim Maas (Taylor Wessing N.V.); Alexander Rubusch (Taylor Wessing); George Seezink (AOMB)

Beklagte

Vertreter: Christof Augenstein (Kather Augenstein); Katharina Brandt (Kather Augenstein); Thomas Kronberger (Grünecker Patent- und Rechtsanwälte)
Richter

Französische Kammer — Einzelrichter anonymisiert.

  • Panel member (anonymized)Presiding Judge and Judge-Rapporteur
  • Panel member (anonymized)Legally Qualified Judge
  • Panel member (anonymized)Technically Qualified Judge
Patente
  • EP2196231
CPC-Codes: A61M2209/045, A61M5/148, A61M5/14244

Technologiebereich: Medical Devices · Drug Delivery

Sektor: Pharmaceutical & Medical

Ausgang
Patent aufrechterhaltenAufrechterhalten wie erteilt
Eingereicht: —
Erste Entscheidung: 18. Dez. 2024
Sprache: —

The Paris Central Division dismissed Tandem Diabetes Care's revocation action against Roche's EP 2 196 231 B1 (ambulatory drug infusion system), maintaining the patent as granted and ordering the claimants to bear the costs of proceedings, finding the grounds for invalidity (including lack of inventive step over prior art Diaz/Robertson/Glejboel) were not proven.

Ansprüche
Streitigall
Aufrechterhaltenall
Hinweise: Paris Central Division dismissed revocation action against EP2196231 in its entirety; patent maintained as granted with no specific claim-by-claim breakdown in excerpts.